Introduction of a new synthetic route about Benzo[d]oxazol-7-amine

The chemical industry reduces the impact on the environment during synthesis,136992-95-5,Benzo[d]oxazol-7-amine,I believe this compound will play a more active role in future production and life.

136992-95-5, In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. Benzo[d]oxazol-7-amine, cas is 136992-95-5,the benzoxazole compound, it is a common compound, a new synthetic route is introduced below.

A mixture of benzooxazol-7-amine (135 mg, 1.01 mmol, Astrazeneca, PCT Appl. WO2003053960), 2.4-dichloropyrimidine (150 mg, 1.01 mmol), DBU (0.197 ml, 1.32 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (58 mg, 0.1 mmol, also named xantphos) and tris(dibenzylideneacetone)dipalladium(0) (58 mg, 0.1 mmol, also named Pd2dba3) in dioxane (3 ml) under argon was irradiated in a Personal Chemistry EMRYS Optimizer EXP microwave synthesisor at 110 C. for 10 minutes. After cooling and evaporation of the solvents, the residue was dissolved in DCM and purified by chromatography on silica gel (eluant: 30% to 60% EtOAc in petroleum ether) to give N-(2-chloropyrimidin-4-yl)benzooxazol-7-amine (88 mg, 35%) as a beige solid. Mass spectrum: MH+ 247

The chemical industry reduces the impact on the environment during synthesis,136992-95-5,Benzo[d]oxazol-7-amine,I believe this compound will play a more active role in future production and life.

Reference:
Patent; AstraZeneca AB; US2011/46108; (2011); A1;,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem

Extracurricular laboratory: Synthetic route of 136992-95-5

The chemical industry reduces the impact on the environment during synthesis,136992-95-5,Benzo[d]oxazol-7-amine,I believe this compound will play a more active role in future production and life.

136992-95-5, In the next few decades, the world population will flourish. As the population grows rapidly and people all over the world use more and more resources, all industries must consider their environmental impact. Benzo[d]oxazol-7-amine, cas is 136992-95-5,the benzoxazole compound, it is a common compound, a new synthetic route is introduced below.

General procedure: 6-Bromo-4-chloroquinoline (1.0 equiv.) and 3,4,5-trimethoxyaniline (1.1 equiv.) were suspended in ethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatography using EtOAc:hexane followed by 1-5% methanol in EtOAc, solvent was removed under reduced pressure to afford the desired product (1, 8-11, 13-31, and 33-43).

The chemical industry reduces the impact on the environment during synthesis,136992-95-5,Benzo[d]oxazol-7-amine,I believe this compound will play a more active role in future production and life.

Reference:
Article; Asquith, Christopher R.M.; Bennett, James M.; Su, Lianyong; Laitinen, Tuomo; Elkins, Jonathan M.; Pickett, Julie E.; Wells, Carrow I.; Li, Zengbiao; Willson, Timothy M.; Zuercher, William J.; Molecules; vol. 24; 22; (2019);,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem

More research is needed about 136992-95-5

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 136992-95-5, and how the biochemistry of the body works.Safety of Benzo[d]oxazol-7-amine

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 136992-95-5, name is Benzo[d]oxazol-7-amine, introducing its new discovery. Safety of Benzo[d]oxazol-7-amine

Towards the development of an in vivo chemical probe for cyclin G associated kinase (GAK)

SGC-GAK-1 (1) is a potent, selective, cell-active chemical probe for cyclin G-associated kinase (GAK). However, 1 was rapidly metabolized in mouse liver microsomes by cytochrome P450-mediated oxidation, displaying rapid clearance in liver microsomes and in mice, which limited its utility in in vivo studies. Chemical modifications of 1 that improved metabolic stability, generally resulted in decreased GAK potency. The best analog in terms of GAK activity in cells was 6-bromo-N-(1H-indazol-6-yl)quinolin-4-amine (35) (IC50 = 1.4 muM), showing improved stability in liver microsomes while still maintaining a narrow spectrum activity across the kinome. As an alternative to scaold modifications we also explored the use of the broad-spectrum cytochrome P450 inhibitor 1-aminobenzotriazole (ABT) to decrease intrinsic clearance of aminoquinoline GAK inhibitors. Taken together, these approaches point towards the development of an in vivo chemical probe for the dark kinase GAK.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 136992-95-5, and how the biochemistry of the body works.Safety of Benzo[d]oxazol-7-amine

Reference£º
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem

The Absolute Best Science Experiment for Benzo[d]oxazol-7-amine

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. category: benzoxazole, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 136992-95-5, in my other articles.

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, category: benzoxazole, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 136992-95-5, Name is Benzo[d]oxazol-7-amine, molecular formula is C7H6N2O

PYRIMIDINE DERIVATIVES

The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of EphB4, and/or EphA2 and/or Src kinases.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. category: benzoxazole, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 136992-95-5, in my other articles.

Reference£º
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem

Simple exploration of 136992-95-5

As the paragraph descriping shows that 136992-95-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.136992-95-5,Benzo[d]oxazol-7-amine,as a common compound, the synthetic route is as follows.

General procedure: 6-Bromo-4-chloroquinoline (1.0 equiv.) and 3,4,5-trimethoxyaniline (1.1 equiv.) were suspended in ethanol (10 mL) and refluxed for 18 h. The crude mixture was purified by flash chromatography using EtOAc:hexane followed by 1-5% methanol in EtOAc, solvent was removed under reduced pressure to afford the desired product (1, 8-11, 13-31, and 33-43)., 136992-95-5

As the paragraph descriping shows that 136992-95-5 is playing an increasingly important role.

Reference£º
Article; Asquith, Christopher R.M.; Bennett, James M.; Su, Lianyong; Laitinen, Tuomo; Elkins, Jonathan M.; Pickett, Julie E.; Wells, Carrow I.; Li, Zengbiao; Willson, Timothy M.; Zuercher, William J.; Molecules; vol. 24; 22; (2019);,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem

Introduction of a new synthetic route about Benzo[d]oxazol-7-amine

With the rapid development of chemical substances, we look forward to future research findings about 136992-95-5

Benzo[d]oxazol-7-amine, cas is 136992-95-5, it is a common heterocyclic compound, the benzoxazole compound, its synthesis route is as follows.,136992-95-5

A mixture of benzooxazol-7-amine (135 mg, 1.01 mmol, Astrazeneca, PCT Appl. WO2003053960), 2.4-dichloropyrimidine (150 mg, 1.01 mmol), DBU (0.197 ml, 1.32 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (58 mg, 0.1 mmol, also named xantphos) and tris(dibenzylideneacetone)dipalladium(0) (58 mg, 0.1 mmol, also named Pd2dba3) in dioxane (3 ml) under argon was irradiated in a Personal Chemistry EMRYS Optimizer EXP microwave synthesisor at 110 C. for 10 minutes. After cooling and evaporation of the solvents, the residue was dissolved in DCM and purified by chromatography on silica gel (eluant: 30% to 60% EtOAc in petroleum ether) to give N-(2-chloropyrimidin-4-yl)benzooxazol-7-amine (88 mg, 35%) as a beige solid. Mass spectrum: MH+ 247

With the rapid development of chemical substances, we look forward to future research findings about 136992-95-5

Reference£º
Patent; AstraZeneca AB; US2011/46108; (2011); A1;,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem

Simple exploration of 136992-95-5

As the paragraph descriping shows that 136992-95-5 is playing an increasingly important role.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.136992-95-5,Benzo[d]oxazol-7-amine,as a common compound, the synthetic route is as follows.

A mixture of benzooxazol-7-amine (135 mg, 1.01 mmol, Astrazeneca, PCT Appl. WO2003053960), 2.4-dichloropyrimidine (150 mg, 1.01 mmol), DBU (0.197 ml, 1.32 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (58 mg, 0.1 mmol, also named xantphos) and tris(dibenzylideneacetone)dipalladium(0) (58 mg, 0.1 mmol, also named Pd2dba3) in dioxane (3 ml) under argon was irradiated in a Personal Chemistry EMRYS Optimizer EXP microwave synthesisor at 110 C. for 10 minutes. After cooling and evaporation of the solvents, the residue was dissolved in DCM and purified by chromatography on silica gel (eluant: 30% to 60% EtOAc in petroleum ether) to give N-(2-chloropyrimidin-4-yl)benzooxazol-7-amine (88 mg, 35%) as a beige solid. Mass spectrum: MH+ 247

As the paragraph descriping shows that 136992-95-5 is playing an increasingly important role.

Reference£º
Patent; AstraZeneca AB; US2011/46108; (2011); A1;,
Benzoxazole – Wikipedia
Benzoxazole | C7H5NO – PubChem